Peter Mac Callum Cancer Centre, Moorabbin Campus, 823-865 Centre Rd, Bentleigh East, VIC 3165, Australia.
Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, Trieste, 34129, Italy.
Future Oncol. 2017 Nov;13(27):2473-2477. doi: 10.2217/fon-2017-0272. Epub 2017 Nov 10.
Treatment of triple-negative breast cancer (TNBC) imposes great challenges, due to a lack of molecular targets. While use of gonadotropin-releasing hormone (GnRH) analogs has been validated in ER-positive breast cancer, this option has not been investigated in TNBC, even though a significant portion of these tumors upregulate GnRH receptors. We performed a meta-analysis of the literature to evaluate the effect of GnRH analogs in TNBC.
Four studies were included in this study.
We detected a non-significant improvement in overall survival with GnRH analogs, while progression-free survival was unchanged.
The majority of the trials evaluated in this analysis were designed to test efficacy of GnRH analogs in preventing premature ovarian failure. This may represent a limitation of our study as these trials were not specifically designed to detect differences in survival outcome measures.
Our results suggest that GnRH analogs may be useful as a targeted therapy in TNBC. Randomized prospective clinical trials are needed to investigate this hypothesis in the clinic.
由于缺乏分子靶点，三阴性乳腺癌（TNBC）的治疗带来了巨大的挑战。虽然促性腺激素释放激素（GnRH）类似物在 ER 阳性乳腺癌中的应用已得到验证，但在 TNBC 中尚未对此进行研究，尽管这些肿瘤中有相当一部分上调 GnRH 受体。我们对文献进行了荟萃分析，以评估 GnRH 类似物在 TNBC 中的作用。
本研究纳入了四项研究。
我们发现 GnRH 类似物可使总生存期非显著改善，而无进展生存期无变化。
本分析中评估的大多数试验旨在测试 GnRH 类似物预防卵巢早衰的功效。这可能是我们研究的一个局限性，因为这些试验并非专门设计用于检测生存结果测量的差异。
我们的结果表明，GnRH 类似物可能对 TNBC 作为靶向治疗有用。需要进行随机前瞻性临床试验以在临床上研究这一假设。
